Skip to main content
Equibles
BDTX logo

BDTX · Black Diamond Therapeutics, Inc.

Track BDTX — free

Use BDTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BDTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.23 -0.04 (-1.76%)
Russell 2000 member Rebalance outlook locked
Market Cap
$130.42M
Shares
57.45M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.27 Open$2.26 Day$2.24–2.32 52W close$1.61–4.87 Avg vol 30d617K Short int6.2M · 10.8% float · 10.4d Short vol65% Last earningsDec 3, 2025 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg +20%
above
RSI (14) 68
neutral
MACD trend Positive
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +32%
trailing
6-month return +6%
trailing
YTD return −7%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.77% of float · ▲ +5.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
98 holders — mid 3-yr range
Squeeze score 77
high risk · 0–100
Fundamentals
Excellent
EPS growth +131%
Y/Y
Free cash flow $29.6M
Balance sheet $21.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −67%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
+20% Bullish
RSI (14)
68 Neutral
MACD trend
Positive Bullish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-6% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.77% of float · ▲ +5.5% MoM · 10.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
98 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 20% Range high $5
vs 200-day avg -8% vs 50-day avg +20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and investments $110.5M the second quarter of 2026 —
CNS ORR (ORR by RANO-BM) 86% As of an April 11, 2026 data cutoff date —
Disease Control Rate (DCR) 91% As of an April 11, 2026 data cutoff date —
Longest duration on therapy 23.5 As of an April 11, 2026 data cutoff date —
Median progression-free survival 15.2 As of an April 11, 2026 data cutoff date —
Objective Response Rate (ORR by RECIST 1.1) 60% As of an April 11, 2026 data cutoff date —
Patients remained on therapy 23 As of an April 11, 2026 data cutoff date —
Patients with EGFRm NSCLC or EGFR-altered GBM treated with silevertinib 200 To date —
Rate of treatment-related adverse events greater than or equal to Grade 3 28% As of an April 11, 2026 data cutoff date —
Net cash provided by operations $29.6M Full Year 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BDTX
Black Diamond Therapeutics, Inc.
this stock
$130.42M -6.6% — — 10.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.8% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +4.6% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $65.12B +25.9% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
98
% held
61.8%
Net QoQ
-3.2M sh
Top holder
NEA Management Company, L…
Held Float
View
Held by Funds
Fund positions
88
View
Short & Settlement
Short Interest Rising
Shares short
6.2M
Days to cover
10.4d
Change
+322.7K sh
View
Short Volume
Short vol %
65%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
2
Value
$4
As of
Jul 22, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$22.4M
EPS diluted
$0.39
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
9
View
Proposed Sales
Value
$310.0K
Shares
50.0K
Filed
Jul 31, 2024
View
Earnings & Events
Earnings Calls
Last call
Dec 3, 2025
View

Performance

5D 20D 120D MTD YTD
BDTX +5.6% +32.4% +5.6% +34.3% -6.6%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY +4.5% +28.4% -9.1% +31.1% -19.7%
Key facts CIK 1701541 CUSIP 09203E105 13F (30d) 89 filings 89 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)